Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)

Clinical trial NCT04733040 · COMPLETED

Trial details

NCT number: NCT04733040
Sponsor: HI-Bio, A Biogen Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Glomerulonephritis Membranous Nephropathy antiPLA2R Positive

Start date: 2021-01-20
Primary completion: 2023-12-14
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.